The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS).
Julia C. Chisholm
Consultant or Advisory Role - Roche
Michela Casanova
Consultant or Advisory Role - Roche
Johannes H. Merks
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Birgit Geoerger
No relevant relationships to disclose
Raphael F. Rousseau
Employment or Leadership Position - Roche
Stock Ownership - Roche
Nicola Moore
Employment or Leadership Position - Roche
Stock Ownership - Roche
Christophe Dhalluin
Employment or Leadership Position - Roche
Odile Oberlin
Honoraria - Roche